Immodulon Therapeutics

Immodulon is a privately owned immuno-oncology company primarily focused on developing novel, safe, effective, and potentially valuable cancer treatments. Our IMM-101-based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. We are currently developing treatments for advanced melanoma, skin cancer, and advanced pancreatic cancer.